December 2012
Volume 53Issue 12p2487-2808
Open Access
COVER: Intracellular cholesterol homeostasis is modulated by the low density lipoprotein
receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds
the LDLR-LDL complex extracellularly, targeting the whole complex for degradation.
Antibodies to PCSK9 may prevent the binding of PCSK9 to the LDLR-LDL complex, allowing
increased recycling of the LDL receptor and increased LDL receptor numbers on the
cell surface. This in turn results in increased catabolism of LDL particles, lowering
plasma LDL cholesterol levels. (See Lambert et al., p. 2515.)...Show more
COVER: Intracellular cholesterol homeostasis is modulated by the low density lipoprotein
receptor (LDLR) pathway. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds
the LDLR-LDL complex extracellularly, targeting the whole complex for degradation.
Antibodies to PCSK9 may prevent the binding of PCSK9 to the LDLR-LDL complex, allowing
increased recycling of the LDL receptor and increased LDL receptor numbers on the
cell surface. This in turn results in increased catabolism of LDL particles, lowering
plasma LDL cholesterol levels. (See Lambert et al., p. 2515.)
